Effectiveness of selenium supplementation in children with autoimmune thyroiditis: A systematic review and meta-analysis

Yuni Hisbiyah
Doctoral Program of Medical Science, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia and Faculty of Medicine, Department of child health, Dr. Soetomo General Hospital, Universitas Airlangga, Surabaya, East Java, Indonesia

Anang Endaryanto
Doctoral Program of Medical Science, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia and Faculty of Medicine, Department of child health, Dr. Soetomo General Hospital, Universitas Airlangga, Surabaya, East Java, Indonesia

Corresponding author email: anang.endaryanto@fk.unair.ac.id

Bagoes Setyoboedi
Doctoral Program of Medical Science, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia and Faculty of Medicine, Department of child health, Dr. Soetomo General Hospital, Universitas Airlangga, Surabaya, East Java, Indonesia

Nur Rochmah
Faculty of Medicine, Department of child health, Dr. Soetomo General Hospital, Universitas Airlangga, Surabaya, East Java, Indonesia

Muhammad Faizi
Faculty of Medicine, Department of child health, Dr. Soetomo General Hospital, Universitas Airlangga, Surabaya, East Java, Indonesia

Citrawati Dyah Kencono Wungu
Faculty of Medicine, Department of Medical Biochemistry, Universitas Airlangga, Surabaya, East Java, Indonesia

Qurrota Ayuni Novia Putri
Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia

Abstract—Deficiencies of Selenium (Se) is correlated with the risk and onset of autoimmune thyroid disease (AITD). The aim of this study...
was to determine the association between Se supplementation and AITD. Methods: Electronic data searches of 4 databases were performed. We assessed the included studies using PRISMA for protocol assurance. Five studies met our inclusion criteria and were analyzed. The predictor covariate in the present study was Se administration. The outcome measures were levels of thyroid peroxidase antibodies (TPO-Ab), thyroglobulin antibody (Tg-Ab), free thyroxine (fT4), and thyroid volume. Results: Of the five studies that met the inclusion criteria, one randomized controlled trial (RCT) was included in the qualitative review, whereas four quasi-experimental studies were included in the meta-analysis. The results showed that Se supplementation significantly reduced TPO-Ab levels (MD 90.85; 95% CI 61.71–120.00; p<0.00001) and fT4 levels (MD 1.52; 95% CI, 0.55–2.50; p=0.002), while the RCT showed that Se supplementation significantly reduced Tg-Ab levels. Conclusions: Se supplementation significantly reduces TPO-Ab and fT4 levels in children and adolescents with AITD. The limited number of studies and population sizes emergence of further studies especially RCTS are needed to make a better meta-analysis.

**Keywords**---autoimmune thyroid disease, Selenium, Thyroid antibody.

**Introduction**

Autoimmune thyroid disease (AITD) is an autoimmune condition of the thyroid gland. The two primary types of AITD are Grave’s Disease (GD) and Hashimoto’s Thyroiditis (HT), which are characterized by T and B cell infiltration of the thyroid and the production of antibodies specific to thyroid antigens (Tomer et al., 2009). The peak onset of AITD occurs between 30 and 50 years of age, but in the early onset of AITD, symptoms manifest between puberty and 20 years of age (Shin et al, 2019). In spite of genetics, environment, and lifestyle as risk factors, deficiencies of micronutrients, including Selenium (Se) is correlated with the risk and onset of AITD (Giovinazzo et al., 2016). The highest concentration of Se in the thyroid gland indicates the importance of Se for thyroid metabolism (Duntas et al., 2015). In addition to its regulatory role in thyroid hormone deiodination, Se preserves the integrity of thyrocytes via glutathione peroxidase (GPx)1 and GPx3 activities (Duntas et al., 2015). Moreover, Se triggers an oxidative burst in response to T-cell receptor stimulation (Huang Z et al., 2012), suppresses human leukocyte antigen-DR isotype molecule development (Balázsz et al, 2012), increases the activity of T regulatory cells and suppresses cytokine secretion. Thus, it prevents follicular cell apoptosis and protects against AITD development (Duntas et al., 2015). Several studies have been conducted, particularly in areas with low Se levels, to determine whether Se supplementation affects the development of thyroid-related immunologic disorders (Ibrahim et al, 2019). However, the results were inconsistent (Schomburg et al, 2021). Systematic reviews have shown that Se supplementation
in adults improves thyroid function and stabilizes thyroid antibody levels at different durations of administration (Zhang et al, 2019).

The development of early-onset AITD in pediatric age is largely genetic, while nongenetic factors such as Se deficiency account for up to 20% (Brix et al., 2001), making it a stronger genetic predisposing risk factor than late-onset AITD in adults (Shin et al, 2019). However, there is an increased prescribing of Se for AITD patients (Negro et al., 2016) and the pediatric population (Filipowicz et al., 2021). While many published reviews highlight the importance of Se supplementation in children and adolescents. Therefore, we conducted a systematic review and meta-analysis to provide a strong basis for the clinical application of Se supplementation in children and adolescents with early-onset AITD.

**Method**

This study was conducted in accordance with the Preferred Reporting Items for Systematic Examination and Meta-Analysis (PRISMA) guidelines. The study protocol was registered in the PROSPERO database (CRD42022309983). [https://www.crd.york.ac.uk/PROSPERO/#myprospero](https://www.crd.york.ac.uk/PROSPERO/#myprospero)

**Search Strategy and selection of studies**

The PubMed, ScienceDirect, Directory of Open Access Journals, and Wiley databases were searched electronically for studies published until February 2022 that assessed the effectiveness of Se supplementation in children and adolescents with autoimmune thyroiditis. The search was conducted using keywords constructed on Medical Subject Heading (MeSH) and other additional keywords: ["Selenium" or "Selenite"] and ["Thyroiditis" or "Autoimmune thyroiditis (AIT)" or "Graves' Disease" or "Hashimoto Thyroiditis" "Hypothyroidism" or "Hyperthyroidism"] and ["Children" or "Pediatric"]. Studies with larger sample sizes were included in the review if duplications were found. We imported all search results into the Mendeley reference manager to remove duplicates and screen. Three researchers (YH, BS, and QA) examined the titles and abstracts of the papers to identify eligible studies and then screened the full texts of all articles separately. Disagreements between the three authors were discussed until a consensus was reached. The PRISMA flow diagram shows the excluded studies and the reasons for their exclusion (Figure 1).
Eligibility and inclusion criteria

The study design included in this review was a clinical trial. The authors independently assessed the titles and abstracts of papers to find relevant research according to the following criteria: (1) Studies assessing the effectiveness of Se supplementation in children with autoimmune thyroiditis (including HT, GD, or both); (2) The study population was children and adolescent (age < 19 years) with AITD (HT was diagnosed based on the presence of Thyroglobulin antibodies (Tg-Ab) and/or Thyroid peroxidase (TPO)-Ab seropositivity, as well as at least one of the following: abnormal thyroid function, enlarged thyroid gland, or thyroid morphological alterations; GD was diagnosed based on finding seropositivity of Thyroid stimulating hormone receptor (TR)-Ab, TPO-Ab, Tg-Ab accompanied by abnormal thyroid function, diffuse goiter, morphological changes, and signs and symptoms related to GD); (3) The full text of the article was accessible; (4) Considering the limited number of similar studies in the pediatric and adolescent population, we included all randomized controlled trials and also quasi-controlled studies which is assigned subjects to groups based on non-random criteria.

Exclusion criteria
The exclusion criteria were as follows: (1) unrelated titles and abstracts; (2) case reports, case series, reviews, and commentaries; (3) incomplete or ungeneralized data; (4) duplicate studies; and (5) unavailable full text.
Data extraction
To provide high-validity data and avoid human errors, three authors (YH, NR, and QA) independently performed data extraction. Any discrepancies, including the lack of concordance in study selection, were resolved by discussion with other investigators (AE, BS, MF, and CD) until a consensus was reached. The following information was extracted from each paper: (1) first author name, (2) year of publication, (3) sample sizes of the case and control groups, (4) age of participants, (5) country, (6) main findings, (7) TPO-Ab levels in the case and control groups, (8) Tg-Ab levels in the case and control groups, (9) free thyroxine (fT4) levels in the case and control groups, and (10) thyroid volume in the case and control groups.

Quality assessment
Three independent reviewers (YH, NR, and QA) assessed the quality of each study based on the checklist of the Joanna Briggs Institute, and if a discrepancy was found, senior researchers (AE, BS, MF, and CD) were consulted. The RCT and quasi-experimental study checklists featured 13 and 9 items, respectively.

Outcome measures
The predicting covariate in this study was Se administration. The outcome measures were TPO-Ab, Tg-Ab, fT4 levels, and thyroid volume. They were determined after an initial search for covariate screening for inclusion in the meta-analysis.

Statistical analysis
The pooled mean difference (MD) and 95% confidence interval of TPO-Ab, Tg-Ab, and fT4 levels and thyroid volume among children with AITD between the intervention and control groups were assessed using a forest plot. The data were checked for heterogeneity and potential publication bias before identifying significant factors. The chi-square and I2 tests were used to measure study heterogeneity.; if p heterogeneity >0.05, and I2 > 50%, a random-effects model was used. The Review Manager version 5.3 was used to analyze the data (Cochrane Collaboration, London, UK). Two authors (YH and QA) conducted statistical analyses independently to avoid methodological errors.

Results
Characteristics of included studies
Our search found 2,751 potentially relevant papers. Among them, 1,965 and 721 papers were excluded because of duplicate records and irrelevant titles, respectively. The abstracts of 65 papers were analyzed, and the full texts of 46 articles were not retrieved because of irrelevant abstracts. Full texts of the remaining 19 papers were assessed for inclusion. Of these, we excluded papers that did not meet the inclusion criteria (n=9), had incomplete data (n=2), or were reviews (n=3). Finally, five studies were included in this review; one RCT was included in the qualitative review, and four studies were included in the meta-analysis. Figure 1 illustrates the paper selection process utilized in our study, while Table 1 highlights the baseline characteristics of the included paper.
<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Participants’ Age, years (mean ± SD)</th>
<th>Country</th>
<th>Sample Size</th>
<th>Selenium level before supplementation</th>
<th>Case Setting</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bonfig et al 2010</td>
<td>Quasi experimental</td>
<td>12.2 ± 2.2</td>
<td>Germany</td>
<td>Control Group (levothyroxine alone): 18 Intervention Group I (levothyroxine + Selenium 100 µg): 13 Intervention Group II (levothyroxine + Selenium 200 µg): 18</td>
<td>Not available</td>
<td>Autoimmune Thyroiditis (newly diagnosed autoimmune Thyroiditis and hypothyroidism, with or without a goiter)</td>
</tr>
<tr>
<td>Onal et al 2012</td>
<td>Quasi experimental</td>
<td>12.2 ± 2.1</td>
<td>Turkey</td>
<td>Control Group (Placebo): 23 Intervention Group (50 µg L-selenomethionine): 30</td>
<td>88.5±17.5 µg/L</td>
<td>Newly diagnosed with Hashimoto Thyroiditis</td>
</tr>
<tr>
<td>Gabulov et al 2019</td>
<td>Quasi experimental</td>
<td>11.0 ± 0.83</td>
<td>Azerbaijan</td>
<td>Control Group (L-Thyroxin): 14 Intervention Group (L-Thyroxin + 100 µg L-selenomethionine): 17</td>
<td>Group I: 68.7 ± 2.34 µg/L Group II: 69.8 ± 1.9 µg/L</td>
<td>Autoimmune Thyroiditis in a state of drug-induced euthyroidism</td>
</tr>
<tr>
<td>Zhang et al 2022</td>
<td>Quasi experimental</td>
<td>7.67 ± 1.22</td>
<td>China</td>
<td>Control Group (15–20 mg methimazole): 50 Intervention Group (15–20 mg methimazole + 50 µg selenium (2 times/d): 53</td>
<td>Not available</td>
<td>Grave’s disease</td>
</tr>
<tr>
<td>Kyrgios et al 2018</td>
<td>RCT</td>
<td>11.3 ± 0.3</td>
<td>Greece</td>
<td>Control Group (Placebo):33 Intervention Group (200 µg L-selenomethionine): 39</td>
<td>Not available</td>
<td>Autoimmune Thyroiditis (euthyroidism or treated hypothyroidism and goiter in thyroid gland ultrasonography)</td>
</tr>
</tbody>
</table>

RCT, randomized controlled trial
The outcome of Se supplementation

Thyroid peroxidase antibodies

In the data synthesis, we included four studies that assessed the association between Se administration and TPO-Ab levels. Pooled analysis revealed that patients receiving Se supplementation had lower TPO-Ab levels than controls (MD, 90.85; 95% CI, 61.71–120.00; p<0.00001) (Figure 2).

Thyroglobulin antibodies

Four studies assessing the correlation between Se administration and Tg-Ab levels were included in the data synthesis. Pooled analysis revealed that Tg-Ab levels were not significantly different between the Se administration group and controls (MD, 9.41; 95% CI, -38.74–57.56; p=0.7) (Figure 2).

Figure 2. Forest Plot of the association between Se supplementation and outcome parameters among children with autoimmune thyroiditis. A. TPO-Ab, B. Tg-Ab, C. fT4, D. Thyroid Volume. TPO-Ab, thyroid peroxidase antibodies; Tg-Ab, thyroglobulin antibody; fT4, free thyroxine.
**Free thyroxin**

Two quasi-experimental studies assessed the association between Se administration and fT4 levels. Pooled analysis revealed that patients receiving Se supplementation had higher fT4 levels than controls (MD, 1.52; 95% CI, 0.55–2.50; p=0.002) (Table 2).

**Thyroid volume**

Two quasi-experimental studies assessed the association between Se administration and thyroid volume. Pooled analysis revealed that thyroid volume was not significantly different between the Se administration group and controls (MD, 2.72; 95% CI, -1.16–6.6; p=0.17) (Table 2).

Table 2. Summary of the Association Between Selenium Administration and Outcome Parameters among Children with Autoimmune Thyroid Disease

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Outcome measure</th>
<th>Mean Difference</th>
<th>95% CI</th>
<th>I2</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control</td>
<td>Selenium</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TPO-Ab (U/m)</td>
<td>447.5 ± 284.3</td>
<td>390 ± 273.5</td>
<td>90.85</td>
<td>61.71, 120.00</td>
</tr>
<tr>
<td></td>
<td>Tg-Ab (U/m)</td>
<td>380.3 ± 494.7</td>
<td>496. ± 814</td>
<td>9.41</td>
<td>-38.74,5 7.56</td>
</tr>
<tr>
<td></td>
<td>fT4 (ng/dL)</td>
<td>3 ± 1</td>
<td>1.5 ± 1</td>
<td>1.52</td>
<td>0.55-2.50</td>
</tr>
<tr>
<td></td>
<td>Thyroid Volume (cm³)</td>
<td>9 ± 3.5</td>
<td>5.5 ± 2.5</td>
<td>2.72</td>
<td>-1.16-6.60</td>
</tr>
</tbody>
</table>

* p <0.05 indicates statistical significance. Note — data are presented using mean ± SD; CI, confidence interval; TPO-Ab, thyroid peroxidase antibodies; Tg-Ab, thyroglobulin antibody; fT4, free thyroxine

**A Randomized Controlled Trial**

A single-center, double-blind, placebo-controlled RCT with 71 children with AITD (14 boys, 57 girls) was included in this study. Participants were randomized into two groups to receive 200 μg daily of organic Se (as L-selenomethionine) (intervention group) or placebo (control group) blindly daily for 6 months. Se supplementation significantly reduced Tg-Ab levels (p=0.021). Although TPO-Ab levels decreased in the intervention group, the difference between the groups was not statistically significant (p=0.219). There was no significant difference in the thyroid volume between the groups (p=0.485).

**Source of heterogeneity and publication bias**

**Heterogeneity among studies**

TPO-Ab and Tg-Ab were assessed using a fixed-effects model (I²≤50%), while fT4 and thyroid volume were assessed using a random-effects model (I²>50%). Evidence of heterogeneity among the studies in our meta-analysis is presented in Table 3.
Table 3. Characteristics of Selenium Supplementation in the included studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Selenium Supplementation</th>
<th>Duration</th>
<th>Type of selenium</th>
<th>Output</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bonfig et al. 2010(^19)</td>
<td><strong>Control Group</strong>: L-Thyroxin</td>
<td>12 Months</td>
<td>Sodium-selenite (non-organic Se)</td>
<td>Tg-Ab levels significantly decreased after 12 months of treatment in control group and intervention group II ((p=0.03 \text{ and } p=0.01,) respectively). The decrease in TPO-Ab concentration was the greatest in intervention group II (reduction of 40.5%) after 12 months of treatment; however, the difference was not significantly significant.</td>
</tr>
<tr>
<td></td>
<td><strong>Intervention Group I</strong> Group II: L-Thyroxin + 100 (\mu g) sodium-selenite</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Intervention Group II</strong>: L-Thyroxin + 200 (\mu g) sodium-selenite</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Onal et al 2012(^29)</td>
<td><strong>Control Group</strong> (Placebo)</td>
<td>3 months</td>
<td>L-selenomethionine (Organic Se)</td>
<td>Significant thyroid volume regression. Thyroid echogenicity, TPO-Ab, and Tg-Ab levels were unchanged after Se treatment</td>
</tr>
<tr>
<td></td>
<td><strong>Intervention Group</strong> (50 (\mu g) L-selenomethionine)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gabulov et al 2019(^32)</td>
<td><strong>Control Group</strong> (L-Thyroxin): <strong>Intervention Group</strong> (L-Thyroxin + 100 (\mu g) L-selenomethionine)</td>
<td>6 months</td>
<td>L-selenomethionine (Organic Se)</td>
<td>TPO-Ab levels significantly decreased after treatment in the intervention group ((p=0.044)). Tg-Ab levels decreased after treatment but not significantly in the intervention group ((p=0.75))</td>
</tr>
<tr>
<td>Zhang et al 2022(^18)</td>
<td><strong>Control Group</strong> (15–20 (mg) methimazole): 50</td>
<td>4-5 weeks</td>
<td>Selenium (not explained in detail)</td>
<td>TPO-Ab and fT4 levels and Thyroid volume significantly decreased after treatment in the intervention group ((p&lt;0.05))</td>
</tr>
<tr>
<td></td>
<td><strong>Intervention Group</strong> (15–20 (mg) methimazole + 50 (\mu g) selenium (2 times/d): 53</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kyrgios et al 2018 (RCT)(^21)</td>
<td><strong>Control Group</strong> (Placebo): 33</td>
<td>6 months</td>
<td>L-selenomethionine (Organic Se)</td>
<td>Tg-Ab levels significantly reduced after treatment in the intervention group, but TPO-Ab levels did not decrease significantly. There was no change in thyroid volume in both groups</td>
</tr>
<tr>
<td></td>
<td><strong>Intervention Group</strong> (200 (\mu g) L-selenomethionine): 39</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
TPO-Ab, thyroid peroxidase antibodies; Tg-Ab, thyroglobulin antibody; fT4, free thyroxine; RCT, randomized controlled trial

Subgroup analysis showed that Se supplementation at a dose of 100 µg significantly reduced TPO-Ab levels (Figure 3, Table 4), while Se administration for ≥ 6 months significantly reduced TPO-Ab levels but not Tg-Ab levels (Figure 4, Table 5).

Figure 3. Subgroup Analyses according to doses of Selenium Supplementation

Table 4. Subgroup Analyses according to doses of Selenium Supplementation

<table>
<thead>
<tr>
<th>Selenium Dose</th>
<th>Number of Studies</th>
<th>Parameters</th>
<th>Outcome Measures</th>
<th>Mean Difference</th>
<th>95% CI</th>
<th>I2</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>TPO-Ab</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>100 µg</td>
<td>3</td>
<td>TPO-Ab</td>
<td>440±244</td>
<td>378 ± 208</td>
<td>91.47</td>
<td>62.13, 120.81</td>
<td>0%</td>
</tr>
</tbody>
</table>

CI, confidence interval; TPO-Ab, thyroid peroxidase antibodies

Figure 4. Forest plot sub group analysis duration treatment for ≥6 months

(A) TPOAb

(B) TGAb
Table 5. Subgroup Analyses according to Duration of Supplementation (≥6 months)

<table>
<thead>
<tr>
<th>Duration of Selenium supplementation</th>
<th>Number of Studies</th>
<th>Parameters</th>
<th>Outcome Measures</th>
<th>Mean Difference</th>
<th>95% CI</th>
<th>I²</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Control</td>
<td>Selenium</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Supplementation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥6 months</td>
<td>2</td>
<td>TPO-Ab</td>
<td>494±323</td>
<td>448±271</td>
<td>81.58</td>
<td>16.54,146.6</td>
<td>0%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tg-Ab</td>
<td>270.5±242</td>
<td>435±707</td>
<td>9.6</td>
<td>-38.72,57.91</td>
<td>0%</td>
</tr>
</tbody>
</table>

* p <0.05 indicates statistical significance
CI, confidence interval; TPO-Ab, thyroid peroxidase antibodies; Tg-Ab, thyroglobulin antibody

**Potential publication bias**
According to the Cochrane Handbook of Systematic Review, the funnel-plot asymmetry test should be used only when there are at least 10 studies in the meta-analysis due to the insufficient power of the test to distinguish the probability of true asymmetry. Therefore, we did not perform funnel-plot analysis to estimate publication bias, as the number of included studies was <10 (Higgins et al., 2019).

**Sensitivity Analysis**
In this meta-analysis, no single study affected the statistical significance of the results after deleting a particular study.

**Discussion**
In this review, we included five studies with a total of 307 children and adolescents with AITD. The meta-analysis was performed on four quasi-experimental studies, and we included one RCT to compare the data. Pooled analysis revealed that Se supplementation significantly reduced TPO-Ab levels. However, in RCT study, TPO-Ab levels decreased but not in significant value. Several meta-analyses on Se supplementation in adults with AITD have reported a significant decrease in TPO-Ab levels (Zhang et al., 2019 and Fang et al., 2016). Analysis of our two subgroups showed a significant reduction in TPO-Ab levels following the administration of 100 µg Se for ≥6 months. A review of adults reported a significantly steeper decline in TPO-Ab levels at a dose of 200 µg Se over 6 months (Duntas et al., 2003). A contrasting result was reported by Anastakilasis et al (2012). Selenium deficiency disrupts the balance of T cells, prompts B lymphocytes to synthesize more anti-thyroid antibodies, induces thyroid peroxidase activity and, as a result, thyroid tissue destruction (Zhang et al., 2022). Se supplementation can effectively improve these pathological and physiological alterations by increasing antioxidant capacity, decreasing thyrocyte damage, and inhibiting TPO-Ab and Tg-Ab expression (Zhang et al., 2022).
Our pooled data showed no significant effect of Se supplementation on the Tg-Ab levels. The RCT included in this study reported a significant reduction in Tg-Ab levels with 200 µg L-selenomethionine for 6 months, which is similar to the findings in an adult study (Anastasilakis, 2012). However, several meta-analyses on adults have shown that Se supplementation has no effect on Tg-Ab levels (Zhang et al., 2019). Thyroglobulin is a physiological circulating antigen. As a result, Tg-Ab concentrations are typically less specific for AITD diagnosis and prognosis (Bonfig et al., 2010).

The fT4 level is commonly used as an indicator of thyroid function. Se supplementation improved fT4 levels in the pooled analyses in this study. Since fT4 was not the primary outcome in the RCT included in this review, there was no data for comparison. A previous study in adults showed that Se supplementation for 3–6 months had a significant effect on serum fT4 levels, indicating higher deiodinase activity induced by L-selenomethionine (Esposito et al., 2017). In this study, thyroid volume decreased after Se supplementation, but not significantly, similar to that in the RCT. In the study of adults with AITD, 12 months of Se supplementation resulted in a moderate decrease in thyroid volume (Balázs et al., 2012). However, the two trials reported no difference (de Farias et al., 2015). In autoimmune diseases, thyroid gland enlargement is caused by the infiltration of lymphocytes, plasma cells, and macrophages (Balázs et al., 2008). As a result, immune-system Se-dependent enzymes can assist avoid tissue damage and induce thyroid volume reductions (Chistiakov et al., 2005).

There was some variation in the patient’s conditions and types of interventions between the studies included in this meta-analysis, which may have led to different results. The dosage of Se used in the included studies varied from 50 to 200 µg/day with a duration of 4-5 weeks to 12 months. However, in the RCT by Kyrgios et al. (2021) participants received 200 µg L-selenomethionine daily for 6 months. Turker et al. discovered that selenomethionine doses more than 100 g daily for 9 months were necessary to reduce TPO-Ab concentrations in adults (Turker, 2006), while our subgroup analyses showed a significant reduction of TPO-Ab with 100 µg of Se for ≥ 6 months. The type of Se administered affects the therapeutic outcomes. In our meta-analysis, three studies used organic Se (L-selenomethionine), and one study used inorganic Se (selenite). Although both organic and inorganic Se can equally increase GPx levels, the storage of organic Se in the body is longer than that of inorganic Se (Alfthan, 2000).

Several studies in adults demonstrated a significant role of Se supplementation in Se deficient subjects in areas that are geographically proven to be low Se status areas, such as Poland (Kryczyk-koziol, 2021) and Germany (Gartner et al., 2002). Unfortunately, not all studies in this meta-analysis examined baseline Se levels before supplementation, although the author stated that Se deficiencies had been reported in their region (Bonfig et al., 2010 and Onal et al., 2012).

The safety window between toxicity and the required dose of Se is narrow, and the inorganic forms of Se are more toxic than the organic (Gorini et al., 2021). In this systematic review, no side effects were reported at any dose. Although Kyrgios et al. (2019) (200 µg L-selenomethionine daily for 6 months) reported a rash during the treatment in one patient, further investigation revealed no correlation. The
recommended Se dosage and duration in children remain unclear. However, the tolerable upper intake level of Se for healthy children aged 1–18 years ranges between 90 and 400 µg/day (Institute of Medicine (US) Panel on Dietary Antioxidants and Related Compounds, 2000). The strength of this study is that it is the first meta-analysis to evaluate the effectiveness of Se supplementation in AITD patients with pediatric and adolescent subjects who have a different predisposition to AITD than adult subjects.

Nevertheless, this study had several limitations: first, the power of analysis may be limited due to the limited number of studies and population sizes; second, there were few RCTs on Se supplementation in children with AITD; third, the heterogeneity in the type, dose, and duration of Se supplementation, and variable data on Se levels prior to supplementation led to differences in results between the meta-analysis and RCT.

**Conclusion**

Our meta-analysis showed that Se supplementation at a dose of 100 µg/day for ≥6 months significantly reduced the TPO-Ab and improved ft4 levels in children and adolescents with AITD. However, these results differ from those reported in RCTs conducted in children. Thus, the emergence of further studies especially RCTS with more complete data are needed to make a better meta-analysis with bigger data to confirm the effects of Se supplementation in children with AITD.

**Acknowledgment**

The authors would like to thank Miss Adila Ulfia Maula Tontowi, a student majoring in Foreign Languages and Intercultural Communication at HSE University Moscow, who helped translate articles published in Russian. We also acknowledge the assistance of Dr. Asri Maharani, Researcher in the Department of Nursing, Faculty of Health and Education, Manchester Metropolitan University, United Kingdom, who advised on this manuscript.

**References**


Bonfig W., Gärtner R., Schmidt H. (2010). Selenium supplementation does not decrease thyroid peroxidase antibody concentration in children and


